ERBB2 and breast carcinoma: Future studies in HER2+ breast cancers would determine conditional loss of MYH9 in HER2+ breast cancer xenografts in vivo and additionally examine the efficacy of inhibitors of ROCK, upstream of NMIIA, in combination with HER2 inhibition.